Paxman Scalp Cooling System has been named as one of Cleveland Clinic’s Top 10 Medical Innovations of 2018.
The list of up-and-coming technologies was selected by a panel of Cleveland Clinic physicians and scientists and was announced at a presentation at the 2017 Medical Innovation Summit.
Now in its 15th year, the annual Medical Innovation Summit is organized by Cleveland Clinic Innovations, the development, and commercialization arm of Cleveland Clinic.
Speaking about the announcement, CEO of Paxman, Richard Paxman said:
We are delighted to have been named as one of the top medical innovations of 2018. My team have worked so hard to develop a system that helps women retain their hair and gives them an alternative to chemotherapy-induced hair loss. I am so proud that all our hard work, research and determination has been recognized in such a prestigious way by the Cleveland Clinic.
The report highlights that ‘newly diagnosed’ cancer patients have a lot to process and for women; the inevitable loss of hair is often one of the hardest side effects.
It goes on to say that the Paxman Scalp Cooler is a new technology that is making its way to the U.S. that will help eliminate this problem from some patients' lists of worries.
Scalp cooling works by reducing the temperature of the scalp a few degrees immediately before, during and after chemotherapy. It has been shown to be effective for preserving hair in women receiving chemotherapy for early-stage breast cancer.
Developed in Huddersfield, UK, the Paxman Scalp Cooling System is the world-leading hair loss prevention system for chemotherapy patients. It has been used by over 100,000 patients in 32 countries and is responsible for helping patients to keep their hair and retain normality during chemotherapy. The system was US cleared by the Food and Drug Administration (FDA) in May 2017.
Chemotherapy works by targeting all rapidly dividing cells in the body. Hair is the second fastest dividing cell, and this is the reason why many chemotherapy drugs cause alopecia. The hair follicles in the growth phase are attacked, resulting in hair loss approximately two weeks after the commencement of chemotherapy treatment.